SiRNA-mediated silencing of β-catenin suppresses invasion and chemosensitivity to doxorubicin in MG-63 osteosarcoma cells

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 1, 2011, Pages 239-245

  Zhang, Fan ^a   Chen, Anmin ^a   Chen, Jianfeng ^a   Yu, Tian ^b   Guo, Fengjing ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Wuhan Aier Eye Hospital   (China)

Author keywords

Gene therapy; Osteosarcoma cell line; siRNA; catenin

Indexed keywords

EID: 79958757876     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Albini A. (1998). Tumor and endothelial cell invasion of basement membranes. The matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms. Pathol Oncol Res, 4, 230-41.
2. Ashikawa K, Shishodia S, Fokt I, et al. (2004). Evidence that activation of nuclear factor-kappaB is essential for the cytotoxic effects of doxorubicin and its analogues. Biochem Pharmacol, 67, 353-64.
3. Bacci G, Longhi A, Versari M, et al. (2006). Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Cancer, 106, 1154-61.
4. Bednarski BK, Baldwin AS Jr, Kim HJ. (2009). Addressing Reported Pro-Apoptotic Functions of NF-κB: Targeted Inhibition of Canonical NF-κB Enhances the Apoptotic Effects of Doxorubicin. PLoS One. doi: 10.1371/journal.pone.0006992.
5. Bielack SS, Kempf-Bielack B, Delling G, et al. (2002). Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol, 20, 776-90.
6. Cai Y, Mohseny AB, Karperien M, et al. (2010). Inactive Wnt/(-catenin pathway in conventional high-grade osteosarcoma. J Pathol, 220, 24-33.
7. Chen K, Fallen S, Abaan HO, et al. (2008). Wnt10b induces chemotaxis of osteosarcoma and correlates with reduced survival. Pediatr Blood Cancer, 51, 349-55.
8. Daino K, Ugolin N, Altmeyer-Morel S, et al. (2009). Gene expression profiling of alpha-radiation-induced rat osteosarcomas: identification of dysregulated genes involved in radiationinduced tumorigenesis of bone. Int J Cancer, 125, 612-20.
9. Deng J, Miller SA, Wang HY, et al. (2002). beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. Cancer Cell, 2, 323-34.
10. Guo Y, Rubin EM, Xie J, et al. (2008). Dominant negative LRP5 decreases tumorigenicity and metastasis of osteosarcoma in an animal model. Clin Orthop Relat Res, 466, 2039-45.
11. Guo Y, Zi X, Koontz Z, et al. (2007). Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells. J Orthop Res, 25, 964-71.
12. Haydon RC, Deyrup A, Ishikawa A, et al. (2002). Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. Int J Cancer, 102, 338-42.
13. Hajra KM, Fearon ER, et al. (2002). Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer, 34, 255-68.
14. Hiendlmeyer E, Regus S, Wassermann S, et al. (2004). Betacatenin up-regulates the expression of the urokinase plasminogen activator in human colorectal tumors. Cancer Res, 64, 1209-14.
15. Hoang BH, Kubo T, Healey JH, et al. (2004). Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer, 109, 106-11.
16. Hoang BH, Kubo T, Healey JH, et al. (2004). Dickkopf 3 inhibits invasion and motility of saos-2 osteosarcoma cells by modulating the wnt-beta-catenin pathway. Cancer Res, 64, 2734-9.
17. Iwaya K, Ogawa H, Kuroda M, et al. (2003). Cytoplasmic and/ or nuclear staining of beta-catenin is associated with lung metastasis. Clin Exp Metastasis, 20, 525-9.
18. Iwoa K, Miyoshi Y, Nawa G, et al. (1999). Frequent beta-catenin abnormalities in bone and soft-tissue tumors. Jpn J Cancer Res, 90, 205-9.
19. Jawad MU, Cheung MC, Clarke J, et al. (2010). Osteosarcoma: improvement in survival limited to high-grade patients only. J Cancer Res Clin Oncol, DOI:10.1007/s00432-010-0923-7
20. Kansara M, Tsang M, Kodjabachian L, et al. (2009). Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma,and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest, 119, 837-51.
21. Karin M. (2006). Nuclear factor-kappaB in cancer development and progression. Nature, 441, 431-6.
22. Klaus A, Birchmeier W. (2008). Wnt signalling and its impact on development and cancer. Nature Rev Cancer, 8, 387-98.
23. Leow PC, Tian Q, Ong ZY, et al. (2009). Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/ betacatenin antagonists against human osteosarcoma cells. Invest New Drugs, DOI: 10.1007/s10637-009-9311-z.
24. Mann B, Gelos M, Siedow A, et al. (1999). Target genes of β-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci, 96, 1603-8.
25. Peifer M, Polakis P. (2000). Wnt signaling in oncogenesis and embryogenesis--a look outside the nucleus. Science, 287, 1606-9.
26. Picci P, Sangiorgi L, Rougraff BT, et al. (1994). Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol, 12, 2699-705,.
27. Polakis P. (2000). Wnt signaling and cancer. Genes Dev, 14, 1837-51.
28. Pu P, Zhang Z, Kang C, et al. (2009). Downregulation of Wnt2 and beta-catenin by siRNA suppresses malignant glioma cell growth. Cancer Gene Ther, 16, 351-61.
29. Reynolds A, Leake D, Boese Q, et al. (2004). Rational siRNA design for RNA interference. Nat Biotechnol, 22, 326-30.
30. Seiki, M. (2003). Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett, 194, 1-11.
31. Takahashi M, Tsunoda T, Seiki M, et al. (2002). Identification of membrane-type matrix metalloproteinase-1 as a target of the (-catenin/Tcf4 complex in human colorectal cancers. Oncogene, 21, 5861-7.
32. Thomas D, Kansara M. (2006). Epigenetic modifications in osteogenic differentiation and transformation. J Cell Biochem, 98, 757-69.
33. Verma UN, Surabhi RM, Schmaltieg A, et al. (2003). Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res, 9, 1291-300.
34. Wang CY, Mayo MW, Baldwin AS, et al. (1996). TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science, 274, 784-7.
35. Wang CY, Mayo MW, Korneluk RG, et al. (1998). NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science, 281, 1680-3.
36. Yang F, Zeng Q, Yu G, et al. (2006). Wnt/beta-catenin signaling inhibits death receptor-mediated apoptosis and promotes invasive growth of HNSCC. Cell Signal, 18, 679-87.
37. Zeng G, Apte U, Cieply B, et al. (2007). siRNA-mediated betacatenin knockdown in human hepatoma cells results in decreased growth and survival. Neoplasia, 9, 951-9.
38. Zucker S, Pei D, Cao J, Lopez-Otin C, et al. (2003). Membrane type-matrix metalloproteinases (MT-MMP). Curr Top Dev Biol, 54, 1-74.